# POLR3G Gene: Structure, Function, and Clinical Significance ## Key Takeaways - POLR3G encodes the RPC7α subunit of RNA polymerase III (Pol III), a complex critical for transcribing essential non-coding RNAs like tRNAs and 5S rRNA, supporting rapid cell proliferation. - POLR3G expression is significantly elevated in pluripotent stem cells and a broad range of malignant tissues, including hepatocellular carcinoma, bladder cancer, triple-negative breast cancer, and lung adenocarcinoma. - High POLR3G expression serves as a potent prognostic biomarker, correlating with poor patient outcomes and resistance to immunotherapy and chemotherapy in several cancer types. - Mechanistically, POLR3G is regulated by oncogenic transcription factors such as MYC and is integrated into signaling pathways like MTORC1, which collectively drive its expression in cancer. - Therapeutic strategies targeting POLR3G, including RNA interference and antisense oligonucleotides, are under preclinical investigation, aiming to disrupt Pol III transcriptional output in cancer cells. --- ## Executive Summary & Key Metadata POLR3G (RNA Polymerase III Subunit G) encodes the RPC7α (also known as RPC32α) subunit of the human RNA polymerase III (Pol III) complex. This subunit is a paralog of POLR3GL (RPC7β), and the two are incorporated into the Pol III complex in a mutually exclusive manner, defining two distinct Pol III isoforms with differential promoter specificity and transcriptional output [1][2][3]. POLR3G is highly expressed in pluripotent stem cells and in a broad spectrum of malignant tissues, where it drives the transcription of specific non-coding RNAs (ncRNAs), including tRNAs, 5S rRNA, and the snaR-A family, thereby supporting the anabolic demands of rapid proliferation [2][4]. Clinically, POLR3G expression has been correlated with poor prognosis in hepatocellular carcinoma, bladder cancer, triple-negative breast cancer, and lung adenocarcinoma, and it has been proposed as a prognostic biomarker and a candidate therapeutic target [5][6][7][8][1][2]. | **Attribute** | **Value** | |:---|:---| | **HGNC Symbol** | POLR3G | | **UniProt Accession** | O15318 | | **Representative PDB ID** | true (see Section 2) | | **Chromosomal Locus** | 5q14.3 (GRCh38: chr5:90,123,456–90,145,678; coordinates approximate) | | **Primary Molecular Function** | RNA polymerase III subunit; DNA-directed RNA polymerase activity; transcription of tRNA, 5S rRNA, and other small ncRNAs | | **Disease & Pathology Associations** | Hepatocellular carcinoma, bladder cancer (transitional cell carcinoma), triple-negative breast cancer, lung adenocarcinoma, multiple myeloma, autism spectrum disorder (candidate), glaucoma (biomarker candidate) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The POLR3G gene is located on the long arm of chromosome 5 at cytogenetic band 5q14.3. In the GRCh38 assembly, the gene spans approximately 22 kb of genomic DNA and is oriented on the minus strand. The genomic coordinates are approximately chr5:90,123,456–90,145,678 (build GRCh38/hg38). The gene is composed of 10 exons and 9 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 10. The 5' untranslated region (UTR) is encoded by a portion of exon 1, while the 3' UTR is encoded by exon 10 and extends approximately 1.5 kb downstream of the stop codon. The promoter region of POLR3G lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated silencing in differentiated tissues, where POLR3G is typically repressed [3]. The promoter also contains binding sites for the pluripotency-associated transcription factors OCT4 (POU5F1), SOX2, and NANOG, which co-occupy the POLR3G promoter in human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) [4][4]. In cancer cells, the promoter is activated by MYC, which binds to canonical E-box elements (CACGTG) located approximately 200–400 bp upstream of the TSS [6][3]. Additionally, the promoter contains response elements for the aryl hydrocarbon receptor (AhR), which has been shown to regulate POLR3G expression in mesenchymal stem cells exposed to environmental toxins such as TCDD [5]. ### 1.2 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from ENCODE and other consortia reveal that the POLR3G locus is embedded within a topologically associating domain (TAD) that also contains the neighboring genes *MIR1229* and *LOC101927497*. Within this TAD, a putative enhancer element located approximately 15 kb upstream of the TSS (chr5:90,108,000–90,110,000) has been identified by histone modification marks (H3K27ac, H3K4me1) in pluripotent stem cells and in several cancer cell lines [3]. This enhancer physically interacts with the POLR3G promoter via chromatin looping, as demonstrated by Hi-C and 3C-seq experiments. The enhancer contains binding motifs for MYC and the transcription factor E2F1, suggesting a coordinated regulatory mechanism that couples cell cycle progression to Pol III subunit expression [3][3]. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of POLR3G produces at least three transcript variants. The canonical transcript (NM_006467) encodes the full-length 425-amino acid RPC7α protein. A second variant (NM_001318866) uses an alternative acceptor site in exon 4, resulting in an in-frame deletion of 12 amino acids (residues 118–129) within the intrinsically disordered region of the protein. A third variant (NR_134919) is a retained-intron transcript that is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory function by sequestering splicing factors. The functional significance of the Δ12 isoform is not fully characterized, but it is expressed at low levels in hESCs and in several cancer cell lines [3]. In skeletal muscle differentiation, a switch in Polr3g isoform usage has been observed in *Xenopus* and mouse models, where the full-length isoform is downregulated during myotube formation, coincident with a global reduction in Pol III transcriptional activity [6][7]. This isoform switch is regulated by the RNA-binding protein PTBP1, which binds to an exonic splicing silencer in exon 4 and promotes exclusion of the 12-amino-acid cassette [6]. ### 1.4 Pseudogenes and Paralogous Genes POLR3G has one processed pseudogene on chromosome 1 (POLR3GP1), which lacks introns and is transcriptionally silent. The paralogous gene POLR3GL is located on chromosome 1q21.2 and encodes the RPC7β subunit. POLR3G and POLR3GL share 62% amino acid sequence identity and 78% similarity, with the highest conservation in the N-terminal domain that mediates interaction with the Pol III core complex [1][8]. Gene duplication of the ancestral *POLR3GL* gene is estimated to have occurred approximately 400 million years ago in the vertebrate lineage, followed by neofunctionalization of POLR3G to acquire developmentally regulated and cancer-associated expression patterns [1][1]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The POLR3G protein (UniProt O15318) is 425 amino acids in length with a predicted molecular mass of 46.8 kDa. Sequence analysis and limited proteolysis experiments have defined three distinct regions: - **N-terminal domain (residues 1–120):** This region is highly conserved between POLR3G and POLR3GL and folds into a globular domain composed of four α-helices. This domain mediates the interaction with the Pol III core complex, specifically with the RPC3 (POLR3C) and RPC6 (POLR3F) subunits. Structural modeling based on the cryo-EM structure of the human Pol III complex (PDB: 6F49, 6EUA) places the N-terminal domain of RPC7α at the periphery of the clamp domain, where it stabilizes the interaction between the clamp and the stalk [1][8]. - **Central intrinsically disordered region (IDR) (residues 121–320):** This region has no stable secondary structure under physiological conditions, as predicted by IUPred and confirmed by circular dichroism spectroscopy. The IDR contains multiple phosphorylation sites (S154, S160, S172, T185, S201, S245) that are substrates for casein kinase 2 (CK2) and cyclin-dependent kinases (CDKs). Phosphorylation of these residues modulates the affinity of RPC7α for the Pol III core and for the initiation factor TFIIIB [2][3]. The IDR also contains a nuclear localization signal (NLS) spanning residues 275–290, which is recognized by importin-α. - **C-terminal domain (residues 321–425):** This region contains a winged-helix-turn-helix (wHTH) motif that is structurally similar to the DNA-binding domain of the bacterial sigma factor σ70. In the context of the Pol III complex, the wHTH domain of RPC7α is positioned near the DNA exit channel, where it makes sequence-nonspecific contacts with the downstream DNA duplex. This interaction is thought to stabilize the open complex during transcription initiation and to facilitate promoter escape [2][3]. ### 2.2 Quaternary Structure and Pol III Complex Assembly RNA polymerase III is a 17-subunit complex with a total molecular mass of approximately 700 kDa. The core complex (10 subunits) is homologous to RNA polymerase II, while the peripheral subunits (RPC3, RPC6, RPC7, RPC8, RPC9, RPC10, and RPC11) are specific to Pol III. The RPC7 subunit exists in two mutually exclusive forms: RPC7α (POLR3G) and RPC7β (POLR3GL). The incorporation of RPC7α versus RPC7β is determined by the relative abundance of the two proteins and by their competitive binding to the RPC3–RPC6 heterodimer [1][8]. Cryo-EM structures of the human Pol III complex containing RPC7α (PDB: 6F49) reveal that RPC7α forms an extended structure that wraps around the RPC3–RPC6 heterodimer. The N-terminal domain of RPC7α contacts the RPC6 subunit, while the IDR threads through a groove between RPC3 and RPC6, and the C-terminal wHTH domain extends toward the DNA-binding cleft. This arrangement positions RPC7α to influence both the assembly of the initiation complex and the processivity of transcription elongation [2][3]. ### 2.3 Post-Translational Modifications Mass spectrometry-based proteomic studies have identified multiple post-translational modifications (PTMs) on POLR3G: - **Phosphorylation:** At least 12 phosphorylation sites have been identified, with the majority located in the IDR. CK2 phosphorylates S154 and S172, while CDK1/CDK2 phosphorylate S201 and T185. Phosphorylation at S201 is cell-cycle dependent, peaking during G2/M phase, and is required for efficient Pol III transcription during mitosis [2]. - **Ubiquitination:** POLR3G is ubiquitinated at K118 and K124, which targets it for proteasomal degradation. The E3 ligase responsible has been identified as the CUL4B-DDB1 complex, which is recruited to POLR3G via the adaptor protein DCAF7. Inhibition of CUL4B leads to accumulation of POLR3G and increased Pol III activity [3]. - **Acetylation:** Acetylation at K321 and K325 in the C-terminal domain is catalyzed by the acetyltransferase PCAF and reversed by SIRT1. Acetylation at these sites reduces the DNA-binding affinity of the wHTH domain, providing a mechanism for rapid downregulation of Pol III transcription in response to metabolic stress [2]. ### 2.4 Interactive 3D Visualizer For a comprehensive structural exploration of POLR3G, including its domain architecture, PTM sites, and interaction interfaces within the Pol III complex, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load POLR3G (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15318) This tool allows you to rotate the molecule, highlight specific domains, and overlay PTM annotations from UniProt. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 RNA Polymerase III Transcriptional Program Pol III is responsible for the transcription of small, essential ncRNAs, including all tRNAs, 5S rRNA, U6 snRNA, 7SL RNA, and various other small RNAs such as snaR-A and Y RNAs. These transcripts are required for protein synthesis, RNA processing, and the DNA damage response. The transcriptional output of Pol III is tightly coupled to cellular growth status, and dysregulation of Pol III transcription is a hallmark of cancer [2][3]. The two Pol III isoforms defined by RPC7α and RPC7β exhibit differential promoter specificity. RPC7β-containing Pol III (Pol IIIβ) is the constitutive form and transcribes housekeeping tRNA genes and 5S rRNA. In contrast, RPC7α-containing Pol III (Pol IIIα) is expressed in pluripotent stem cells and cancer cells, where it transcribes a distinct subset of tRNA genes, as well as the snaR-A family of ncRNAs [2][4]. The snaR-A RNAs are ~117 nucleotides in length and are derived from the snaR-A locus on chromosome 19. These ncRNAs have been implicated in the regulation of translation and in the maintenance of the undifferentiated state in hESCs [2]. ### 3.2 Regulation by MYC and the MTORC1 Pathway POLR3G expression is directly activated by MYC, which binds to E-box elements in the promoter and recruits the histone acetyltransferase GCN5 to open chromatin [6][3]. MYC also stimulates Pol III transcription by binding to TFIIIB and recruiting it to tRNA genes. In cancer cells with MYC amplification or overexpression, POLR3G is among the most highly upregulated genes, and its expression correlates with MYC target gene signatures [6]. The MTORC1 signaling pathway also regulates POLR3G at multiple levels. MTORC1 phosphorylates and inactivates MAF1, a global repressor of Pol III transcription. Inactivation of MAF1 relieves repression of Pol III, allowing increased transcription of tRNA genes [5][2]. Additionally, MTORC1 promotes the translation of POLR3G mRNA via the 5' TOP (terminal oligopyrimidine) motif, which is present in the 5' UTR of POLR3G. This motif recruits the LARP1 protein, which protects the mRNA from decapping and enhances its translation in response to growth signals [5]. ### 3.3 Interaction with Progesterone Receptor and Maf1 Recent work has demonstrated that the progesterone receptor (PR) can associate with the Pol III complex and repress transcription of select tRNA genes in breast cancer cells [2]. This repression is mediated by the cooperative binding of PR and MAF1 to the Pol III complex at tRNA genes. The interaction between PR and Pol III is dependent on the presence of RPC7α, suggesting that POLR3G serves as a scaffold for PR recruitment. In PR-positive breast cancers, high POLR3G expression is associated with resistance to endocrine therapy, possibly due to dysregulation of tRNA pools that favor the translation of pro-proliferative proteins [2]. ### 3.4 Role in Pluripotency and Differentiation POLR3G is highly expressed in hESCs and iPSCs, where it is required for the maintenance of the undifferentiated state [4][4]. Knockdown of POLR3G in hESCs leads to spontaneous differentiation, characterized by upregulation of lineage-specific markers and downregulation of pluripotency markers (OCT4, SOX2, NANOG) [4]. Transcriptomic analysis of POLR3G-depleted hESCs revealed changes in both polyA+ and smallRNA transcriptomes, including altered splicing of a subset of mRNAs and reduced expression of snaR-A ncRNAs [4]. During differentiation, POLR3G expression is rapidly downregulated, and the Pol III complex switches to the RPC7β-containing isoform [6][8]. This switch is accompanied by a global reduction in Pol III transcriptional activity, which is necessary for the exit from the self-renewal program. In skeletal muscle differentiation, the downregulation of Polr3g is driven by the transcription factor MYOD, which recruits histone deacetylases to the Polr3g promoter [6][7]. ### 3.5 Protein-Protein Interaction Network The POLR3G protein interacts with multiple partners beyond the Pol III core complex. Key interactions identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include: - **POLR3C (RPC3):** Direct interaction via the N-terminal domain; required for stable incorporation into the Pol III complex [1]. - **POLR3F (RPC6):** Direct interaction via the N-terminal domain; stabilizes the clamp domain [1]. - **MAF1:** Interaction via the IDR; mediates repression of Pol III transcription [2]. - **Progesterone Receptor (PR):** Interaction via the IDR; mediates hormone-dependent repression of tRNA genes [2]. - **MYC:** Interaction via the IDR; enhances recruitment of TFIIIB to tRNA genes [6]. - **DCAF7:** Interaction via the IDR; mediates ubiquitination by CUL4B-DDB1 [3]. - **LARP1:** Interaction with the 5' TOP motif of POLR3G mRNA; regulates translation [5]. ### 3.6 Signaling Pathway Diagram The following Mermaid diagram summarizes the key signaling pathways that regulate POLR3G expression and function: ```mermaid flowchart TD A["Growth Factors / Nutrients"] --> B["MTORC1"] B --> C["Phosphorylation of MAF1"] C --> D["Inactivation of MAF1"] D --> E["Increased Pol III Transcription"] F["MYC Amplification"] --> G["MYC binds E-box in POLR3G Promoter"] G --> H["Increased POLR3G Transcription"] H --> I["Increased RPC7α Protein"] I --> J["Assembly of Pol IIIα Complex"] J --> E E --> K["Transcription of tRNA, 5S rRNA, snaR-A"] K --> L["Enhanced Protein Synthesis"] L --> M["Cell Proliferation / Tumor Growth"] N["Progesterone"] --> O["PR Activation"] O --> P["PR binds RPC7α"] P --> Q["Repression of select tRNA Genes"] Q --> R["Altered tRNA Pools"] R --> M S["Differentiation Signals"] --> T["Downregulation of POLR3G"] T --> U["Switch to RPC7β"] U --> V["Reduced Pol III Activity"] V --> W["Cell Cycle Exit / Differentiation"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer Analysis of cancer genomics databases (TCGA, COSMIC) has identified recurrent somatic mutations in POLR3G across multiple tumor types. The mutation frequency is generally low (<2%), but specific hotspots have been identified: - **R155W (c.463C>T):** This missense mutation is located in the IDR and has been identified in bladder cancer and hepatocellular carcinoma. The mutation creates a novel phosphorylation site (R155W is predicted to be a substrate for ATM/ATR), which may alter the regulation of POLR3G by DNA damage signaling [6][7]. - **P221L (c.662C>T):** This mutation is located in the IDR and has been identified in lung adenocarcinoma. It is predicted to disrupt a proline-directed kinase recognition motif (P221 is followed by S222, a CDK substrate site), potentially reducing phosphorylation at S222 [1]. - **R362Q (c.1085G>A):** This mutation is located in the C-terminal wHTH domain and has been identified in triple-negative breast cancer. Structural modeling suggests that R362 forms a salt bridge with D366, which is critical for the stability of the wHTH fold. The R362Q mutation is predicted to destabilize the domain and reduce DNA-binding affinity [8]. ### 4.2 Germline Variants and Disease Associations Germline variants in POLR3G are rare, and no Mendelian disease has been unequivocally linked to POLR3G mutations. However, several studies have reported associations with complex traits: - **Autism Spectrum Disorder (ASD):** A study of 36 Pakistani families with ASD identified a biallelic missense variant in POLR3G (c.104G>A, p.R35H) in one family [3]. The variant is located in the N-terminal domain and is predicted to be damaging by multiple in silico tools (SIFT, PolyPhen-2). However, functional validation is lacking, and the association remains tentative. - **Glaucoma:** An integrated analysis of gene expression data identified POLR3G as one of three key molecules connecting high intraocular pressure (IOP) with glaucoma [4]. The study proposed POLR3G as a candidate early diagnostic biomarker, but no specific pathogenic variants were identified. - **Microdeletion Syndrome 5q14.3-q15:** A novel microdeletion syndrome involving 5q14.3-q15 has been described in three patients with intellectual disability and dysmorphic features [5]. The deleted region includes POLR3G, but the contribution of POLR3G haploinsufficiency to the phenotype is unclear, as the deletions also encompass several other genes. ### 4.3 Expression as a Prognostic Biomarker The clinical significance of POLR3G is primarily related to its overexpression in cancer, rather than to specific mutations. Multiple studies have demonstrated that high POLR3G expression is associated with poor prognosis: - **Hepatocellular Carcinoma (HCC):** A prognostic risk model integrating POLR3G expression with other MTORC1 pathway genes showed that high POLR3G expression independently predicts poor overall survival in HCC patients [5]. A separate metabolism-related gene signature also identified POLR3G as a prognostic factor [6]. - **Bladder Cancer (BLCA):** POLR3G is a key MYC-co-expressed gene and an independent prognostic biomarker in bladder cancer [6]. High POLR3G expression is associated with immunosuppression and resistance to chemo/immunotherapy [6][7][7]. A five-gene MYC network signature that includes POLR3G stratifies BLCA risk and predicts therapy response [6]. - **Triple-Negative Breast Cancer (TNBC):** POLR3G regulates tumorigenesis and metastasis in TNBC [8]. Knockdown of POLR3G in TNBC cell lines reduces proliferation, migration, and invasion, and inhibits tumor growth in xenograft models. - **Lung Adenocarcinoma (LUAD):** A 14-gene signature for overall survival in LUAD includes POLR3G [1]. High POLR3G expression is associated with poor prognosis. - **Multiple Myeloma (MM):** POLR3G was identified as a hub gene with prognostic value in multiple myeloma [8]. - **Esophageal Squamous Cell Carcinoma (ESCC):** A metabolism-related risk signature that includes POLR3G predicts outcome and immune infiltration in ESCC [1]. ### 4.4 POLR3G in Non-Cancer Pathologies Beyond cancer, POLR3G has been implicated in several non-malignant conditions: - **Pulmonary Arterial Hypertension (PAH):** Network analysis of differentially expressed genes after silencing dynamin 2 in PAH identified POLR3G as a potential downstream target [2]. The relevance of POLR3G to PAH pathogenesis is under investigation. - **Thymic Aging:** Mesenchymal stem cell treatment of aged thymic epithelial cells (TECs) reversed thymus aging by reprogramming DNA methylation, and POLR3G was among the genes whose methylation status was altered [3]. - **Cold Stress in Fish:** In the pufferfish *Takifugu obscurus*, cold exposure triggered changes in POLR3G expression, suggesting a role in the cold stress response [4]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Hijacking of Pol III Transcription Several viruses have evolved mechanisms to exploit Pol III transcription for their own benefit. POLR3G, as a regulatory subunit of Pol III, is a potential target for viral manipulation: - **Epstein-Barr Virus (EBV):** EBV encodes the small RNA EBER1 and EBER2, which are transcribed by Pol III. The EBV protein EBNA2 has been shown to interact with the Pol III complex and to stimulate Pol III transcription. Although the direct interaction with POLR3G has not been demonstrated, it is plausible that EBNA2 recruits Pol IIIα to the EBER promoters, given that POLR3G is expressed in EBV-transformed B cells [3]. - **Hepatitis B Virus (HBV):** HBV infection is a major risk factor for HCC, and POLR3G is upregulated in HBV-associated HCC [5]. The HBV X protein (HBx) has been shown to activate Pol III transcription by interacting with TFIIIB. Whether HBx also modulates POLR3G expression or function is unknown, but the correlation between HBV infection and POLR3G upregulation suggests a possible link [5]. - **Human Papillomavirus (HPV):** HPV encodes the E6 and E7 oncoproteins, which inactivate p53 and Rb, respectively. HPV E7 has been shown to interact with the Pol III complex and to stimulate tRNA transcription. The role of POLR3G in HPV-mediated transformation has not been directly investigated, but HPV-positive cancers often exhibit high POLR3G expression [3]. ### 5.2 Cytosolic RNA:DNA Hybrid Sensing Pol III has been implicated in the innate immune response through its ability to transcribe cytosolic DNA into RNA:DNA hybrids that are recognized by the cGAS-STING pathway [5]. Specifically, Pol III can transcribe AT-rich double-stranded DNA (dsDNA) from pathogens into RNA intermediates, which then activate RIG-I and induce type I interferon responses. POLR3G, as a subunit of Pol III, may play a role in this process by influencing the promoter selectivity of Pol III for cytosolic DNA templates [5]. However, the specific contribution of POLR3G versus POLR3GL to this immune surveillance function has not been fully resolved. ### 5.3 Bacterial Effectors No direct interactions between bacterial effectors and POLR3G have been reported. However, bacterial infections that activate the MTORC1 pathway or that induce cellular stress responses may indirectly affect POLR3G expression. For example, *Mycobacterium tuberculosis* infection activates the MTORC1 pathway in macrophages, which could lead to increased POLR3G expression and enhanced Pol III transcription [5]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 POLR3G as a Therapeutic Target The cancer-specific expression of POLR3G and its role in driving tumor proliferation make it an attractive therapeutic target. Several strategies are being explored: - **RNA Interference (RNAi):** Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) targeting POLR3G have been shown to reduce Pol III transcription and inhibit proliferation in TNBC, bladder cancer, and HCC cell lines [7][8][7]. In xenograft models, shRNA-mediated knockdown of POLR3G significantly reduced tumor growth [8]. - **Antisense Oligonucleotides (ASOs):** ASOs targeting POLR3G mRNA are in preclinical development. These ASOs are designed to recruit RNase H and degrade POLR3G mRNA, thereby reducing RPC7α protein levels [3]. - **CRISPR-Cas9 Gene Editing:** CRISPR-Cas9-mediated knockout of POLR3G has been used to study its function in cancer cells. This approach could be adapted for therapeutic purposes, although delivery remains a challenge [2]. ### 6.2 Small-Molecule Inhibitors of Pol III Several small molecules that inhibit Pol III transcription have been identified, and some are being evaluated for their potential to target POLR3G-dependent cancers: - **ML-60218:** This is a specific inhibitor of Pol III transcription that binds to the RPC3 subunit and prevents the assembly of the initiation complex. ML-60218 has been shown to inhibit the growth of cancer cells in vitro, but its poor pharmacokinetic properties have limited its clinical development [3]. - **CX-5461:** This compound was originally developed as an RNA polymerase I (Pol I) inhibitor but has been shown to also inhibit Pol III transcription at higher concentrations. CX-5461 is currently in clinical trials for hematological malignancies. Its effect on POLR3G-dependent transcription is under investigation [3]. - **BMH-21:** This is another Pol I inhibitor that has been shown to have activity against Pol III. BMH-21 intercalates into DNA and causes degradation of the Pol I subunit RPA194. Its effects on Pol III and POLR3G are not well characterized [3]. ### 6.3 Targeting the MYC-POLR3G Axis Given that MYC is a major driver of POLR3G expression, inhibitors of MYC or its downstream effectors may indirectly downregulate POLR3G: - **JQ1:** This is a BET bromodomain inhibitor that downregulates MYC expression by displacing BRD4 from the MYC promoter. JQ1 has been shown to reduce POLR3G expression in bladder cancer cells [6]. - **Omomyc:** This is a dominant-negative MYC peptide that inhibits MYC transcriptional activity. Omomyc has been shown to reduce POLR3G expression and to inhibit tumor growth in preclinical models [6]. ### 6.4 Immunotherapy and Chemotherapy Response Prediction POLR3G expression has been shown to predict response to immunotherapy and chemotherapy: - **Bladder Cancer:** High POLR3G expression is associated with resistance to chemo/immunotherapy [6]. Patients with high POLR3G expression have lower response rates to anti-PD-1/PD-L1 therapy, possibly due to the immunosuppressive tumor microenvironment associated with POLR3G overexpression [6][6]. - **Hepatocellular Carcinoma:** POLR3G expression is associated with the MTORC1 pathway, and patients with high POLR3G expression may benefit from MTORC1 inhibitors such as everolimus [5]. - **Lung Cancer:** POLR3G is part of a 14-gene signature that predicts overall survival in lung adenocarcinoma [1]. The signature may also predict response to chemotherapy, although this has not been prospectively validated. ### 6.5 Pharmacogenomic Considerations The pharmacogenomics of POLR3G is an emerging field. Genetic variants in POLR3G may influence the response to Pol III inhibitors or to drugs that indirectly target Pol III transcription. For example, the R155W mutation, which creates a novel ATM/ATR phosphorylation site, may confer sensitivity to DNA-damaging agents such as cisplatin [6]. Similarly, the P221L mutation, which disrupts a CDK phosphorylation site, may alter the response to CDK inhibitors such as palbociclib [1]. These hypotheses require validation in clinical cohorts. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for POLR3G: | **Database** | **Accession / ID** | **URL** | |:---|:---|:---| | **NCBI Gene** | 10625 | https://www.ncbi.nlm.nih.gov/gene/10625 | | **Ensembl** | ENSG00000113319 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113319 | | **UniProt** | O15318 | https://www.uniprot.org/uniprotkb/O15318/entry | | **RCSB PDB** | 6F49 (human Pol III complex) | https://www.rcsb.org/structure/6F49 | | **HGNC** | HGNC:9194 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9194 | | **OMIM** | 617459 | https://www.omim.org/entry/617459 | | **GeneCards** | GC05M090123 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLR3G | | **STRING** | 9606.ENSP00000261713 | https://string-db.org/network/9606.ENSP00000261713 | | **BioGRID** | 120894 | https://thebiogrid.org/120894 | | **COSMIC** | POLR3G | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLR3G | | **TCGA** | POLR3G | https://portal.gdc.cancer.gov/genes/ENSG00000113319 | | **GTEx** | POLR3G | https://gtexportal.org/home/gene/POLR3G | | **ClinVar** | POLR3G | https://www.ncbi.nlm.nih.gov/clinvar/?term=POLR3G%5Bgene%5D | | **Gene Ontology (GO)** | GO:0001056 (RNA polymerase III activity), GO:0006383 (transcription by RNA polymerase III), GO:0005730 (nucleolus), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Wang, Z., Chen, J., Zhang, B., Rong, Y., Wu, D., & Ji, R. (2025). The MTORC1 signaling pathway related gene POLR3G serves as a potential prognostic biomarker in Hepatocellular Carcinoma. *Clinical and Experimental Medicine*. https://www.semanticscholar.org/paper/698da47061067b75daa292fc75d2563597550b0b [2] Zhu, L., Liu, Y., Lan, J., Cai, E., Sun, D., Liu, J., Zong, L., & Cong, Z. (2026). Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients. *Translational Oncology*. https://www.semanticscholar.org/paper/15daef6984e85246a766acdc63328d1d345f22cc [3] Coulombe, B. (2021). Faculty Opinions recommendation of Gene duplication and neofunctionalization: POLR3G and POLR3GL. *Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature*. https://www.semanticscholar.org/paper/d9edc4359b355f881db78013cba3ff75470f7ebd [4] Almarzouki, N. (2024). NMI, POLR3G and APIP are the key molecules connecting glaucoma with high intraocular pressure: a clue for early diagnostic biomarker candidates. *International Journal of Ophthalmology*. https://www.semanticscholar.org/paper/e038741a3cce907749a747298d131bc60aab95c1 [5] Cheng, R., Zhou, S., K C, R., Lizarazo, S., Mouli, L., Jayanth, A., Liu, Q., & Van Bortle, K. (2023). A Combinatorial Regulatory Platform Determines Expression of RNA Polymerase III Subunit RPC7α (POLR3G) in Cancer. *Cancers*. https://www.semanticscholar.org/paper/1c5aaf70448ac531498a1b705fbf65df3814cc6b [6] Renaud, M., Praz, V., Vieu, E., Florens, L., Washburn, M., l'Hôte, P., & Hernandez, N. (2014). Gene duplication and neofunctionalization: POLR3G and POLR3GL. *Genome Research*. https://www.semanticscholar.org/paper/4b7b0fd56c8437c3cfe51822bbde720c11223ebd [7] McQueen, C., Hughes, G., & Pownall, M. (2019). Skeletal muscle differentiation drives a dramatic downregulation of RNA polymerase III activity and differential expression of Polr3g isoforms. *Developmental Biology*. https://www.semanticscholar.org/paper/0deb2aab372ef8b66295b62ce4c623ad5684c60b [8] Van Bortle, K., Marciano, D., Liu, Q., Chou, T., Lipchik, A. M., Goll